Association of anti-Ro/SSA antibody with response to biologics in patients with rheumatoid arthritis

References

• Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64:625–39.
   PubMed Web of Science ®Google Scholar
• Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006; 65:453–8.
   PubMed Web of Science ®Google Scholar
• Meyer O, Labarre C, Dougados M, Goupille Ph, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003;62:120–6.
   PubMed Web of Science ®Google Scholar
• Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis. 2003;62:427–30.
   PubMed Web of Science ®Google Scholar
• Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol. 2008;28:445–55.
   PubMed Web of Science ®Google Scholar
• Eriksson C1, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403–7.
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Franceschini F, Quinzanini M, Manera C, Del Papa N, Maglione W, et al. Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. Clin Exp Rheumatol. 2006;24:59–64.
   PubMed Web of Science ®Google Scholar
• Schneeberger E, Citera G, Heredia M, Maldonado Cocco J. Clinical significance of anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol. 2008;27:517–19.
   PubMed Web of Science ®Google Scholar
• Boire G, Ménard HA. Clinical significance of anti-Ro (SSA) antibody in rheumatoid arthritis. J Rheumatol. 1988;15:391–4.
   PubMed Web of Science ®Google Scholar
• Boire G, Ménard HA, et al. Rheumatoid arthritis: anti-Ro antibodies define a non-HLA-DR4 associated clinicoserological cluster. J Rheumatol. 1993;20:1654–60.
   PubMed Web of Science ®Google Scholar
• Brown LE, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Liao KP. Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology (Oxford). 2015;54:816–20.
   PubMed Web of Science ®Google Scholar
• Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2346–54.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatismassociation 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.
   PubMed Web of Science ®Google Scholar
• Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity. Mod Rheumatol. 2004;14:425–34.
   PubMedGoogle Scholar
• Tsuboi H, Asashima H, Takai C, Hagiwara S, Hagiya C, Yokosawa M, et al. Primary and secondary surveys on epidemiology of Sjögren's syndrome in Japan. Mod Rheumatol. 2014;24:464–70.
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, et al. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients. Clin Exp Rheumatol. 2007;25:676–83.
   PubMed Web of Science ®Google Scholar
• van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008;27:1021–8.
   PubMed Web of Science ®Google Scholar
• van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007;66:253–6.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–9.
   PubMed Web of Science ®Google Scholar
• de Souza TR, de Albuquerque Tavares Carvalho A, Duarte ÂP, Porter SR, Leão JC, Gueiros LA. Th1 and Th2 polymorphisms in Sjögren's syndrome and rheumatoid arthritis. J Oral Pathol Med. 2014;43:418–26.
   PubMed Web of Science ®Google Scholar
• Mieliauskaite D, Venalis P, Dumalakiene I, Venalis A, Distler J. Relationship between serum levels of TGF-beta1 and clinical parameters in patients with rheumatoid arthritis and Sjögren's syndrome secondary to rheumatoid arthritis. Autoimmunity. 2009;42:356–8.
   PubMed Web of Science ®Google Scholar
• Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204:33–9.
   PubMed Web of Science ®Google Scholar
• Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther. 2004;6:R264–72.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A, et al. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol. 2004;22:756–8.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, et al. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity. 2005;38:155–60.
   PubMed Web of Science ®Google Scholar
• Yukawa N, Fujii T, Kondo-Ishikawa S, Yoshifuji H, Kawabata D, Nojima T et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther. 2011;13:R213.
   Google Scholar
• Pesce B, Soto L, Sabugo F, Wurmann P, Cuchacovich M, Lopez MN, et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol. 2013;171:237–42.
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi H, Ebe H, et al. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks. Mod Rheumatol. 2015;25:187–93.
   PubMed Web of Science ®Google Scholar